These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 14730210)

  • 1. Myeloperoxidase gene variation and coronary flow reserve in young healthy men.
    Mäkelä R; Laaksonen R; Janatuinen T; Vesalainen R; Nuutila P; Jaakkola O; Knuuti J; Lehtimäki T
    J Biomed Sci; 2004; 11(1):59-64. PubMed ID: 14730210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of hepatic lipase C-480T polymorphism on coronary flow reserve in young men is independent of the plasma cholesterol level.
    Fan YM; Laaksonen R; Janatuinen T; Vesalainen R; Laine H; Raitakari OT; Nuutila P; Knuuti J; Rontu R; Lehtimäki T
    Atherosclerosis; 2006 Oct; 188(2):391-7. PubMed ID: 16330034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic lipase gene variation is related to coronary reactivity in healthy young men.
    Fan Y; Laaksonen R; Janatuinen T; Vesalainen R; Nuutila P; Koivula T; Knuuti J; Lehtimäki T
    Eur J Clin Invest; 2001 Jul; 31(7):574-80. PubMed ID: 11454011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oestrogen receptor gene variation is a determinant of coronary reactivity in healthy young men.
    Lehtimäki T; Laaksonen R; Mattila KM; Janatuinen T; Vesalainen R; Nuutila P; Laakso J; Jaakkola O; Koivula T; Knuuti J
    Eur J Clin Invest; 2002 Jun; 32(6):400-4. PubMed ID: 12059984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paraoxonase gene polymorphisms and coronary reactivity in young healthy men.
    Malin R; Knuuti J; Janatuinen T; Laaksonen R; Vesalainen R; Nuutila P; Jokela H; Laakso J; Jaakkola O; Solakivi T; Lehtimäki T
    J Mol Med (Berl); 2001 Aug; 79(8):449-58. PubMed ID: 11511975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-induced increment of coronary flow reserve is not abolished by dexamethasone in healthy young men.
    Laine H; Nuutila P; Luotolahti M; Meyer C; Elomaa T; Koskinen P; Rönnemaa T; Knuuti J
    J Clin Endocrinol Metab; 2000 May; 85(5):1868-73. PubMed ID: 10843167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High oxidized LDL and elevated plasma homocysteine contribute to the early reduction of myocardial flow reserve in healthy adults.
    Laaksonen R; Janatuinen T; Vesalainen R; Lehtimäki T; Elovaara I; Jaakkola O; Jokela H; Laakso J; Nuutila P; Punnonen K; Raitakari O; Saikku P; Salminen K; Knuuti J
    Eur J Clin Invest; 2002 Nov; 32(11):795-802. PubMed ID: 12423319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of myocardial blood flow by lipid-lowering therapy with pravastatin is modulated by apolipoprotein E genotype.
    Ilveskoski E; Lehtimäki T; Laaksonen R; Janatuinen T; Vesalainen R; Nuutila P; Laippala P; Karhunen PJ; Knuuti J
    Scand J Clin Lab Invest; 2007; 67(7):723-34. PubMed ID: 17852827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association between coronary flow reserve and development of coronary calcifications: a follow-up study for 11 years in healthy young men.
    Uusitalo V; Saraste A; Kajander S; Luotolahti M; Wendelin-Saarenhovi M; Sundell J; Raitakari O; Knuuti J
    Eur Heart J Cardiovasc Imaging; 2013 Aug; 14(8):812-8. PubMed ID: 23264601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-1B genotype modulates the improvement of coronary artery reactivity by lipid-lowering therapy with pravastatin: a placebo-controlled positron emission tomography study in young healthy men.
    Lehtimäki T; Laaksonen R; Janatuinen T; Vesalainen R; Nuutila P; Mattila K; Ilveskoski E; Luomala M; Saikku P; Knuuti J; Hurme M
    Pharmacogenetics; 2003 Oct; 13(10):633-9. PubMed ID: 14515062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelial nitric oxide synthase genotype modulates the improvement of coronary blood flow by pravastatin: a placebo-controlled PET study.
    Kunnas TA; Lehtimäki T; Laaksonen R; Ilveskoski E; Janatuinen T; Vesalainen R; Nuutila P; Karhunen PJ; Knuuti J; Nikkari ST
    J Mol Med (Berl); 2002 Dec; 80(12):802-7. PubMed ID: 12483466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation of myeloperoxidase promoter polymorphism and long-term hormone replacement therapy to oxidized low-density lipoprotein autoantibodies in postmenopausal women.
    Mäkelä R; Dastidar P; Jokela H; Jaakkola O; Saarela M; Punnonen R; Lehtimäki T
    Scand J Clin Lab Invest; 2006; 66(5):371-83. PubMed ID: 16901848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coronary flow reserve is impaired in young men with familial hypercholesterolemia.
    Pitkänen OP; Raitakari OT; Niinikoski H; Nuutila P; Iida H; Voipio-Pulkki LM; Härkönen R; Wegelius U; Rönnemaa T; Viikari J; Knuuti J
    J Am Coll Cardiol; 1996 Dec; 28(7):1705-11. PubMed ID: 8962555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin sensitivity and coronary vasoreactivity: insulin sensitivity relates to adenosine-stimulated coronary flow response in human subjects.
    Dagres N; Saller B; Haude M; Hüsing J; von Birgelen C; Schmermund A; Sack S; Baumgart D; Mann K; Erbel R
    Clin Endocrinol (Oxf); 2004 Dec; 61(6):724-31. PubMed ID: 15579187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of myeloperoxidase promoter polymorphism with carotid atherosclerosis is abolished in patients with type 2 diabetes.
    Mäkelä R; Loimaala A; Nenonen A; Mercuri M; Vuori I; Huhtala H; Oja P; Bond G; Koivula T; Lehtimäki T
    Clin Biochem; 2008 May; 41(7-8):532-7. PubMed ID: 18280811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive quantification of regional myocardial flow reserve in patients with coronary atherosclerosis using nitrogen-13 ammonia positron emission tomography. Determination of extent of altered vascular reactivity.
    Beanlands RS; Muzik O; Melon P; Sutor R; Sawada S; Muller D; Bondie D; Hutchins GD; Schwaiger M
    J Am Coll Cardiol; 1995 Nov; 26(6):1465-75. PubMed ID: 7594072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coronary circulatory function in patients with the metabolic syndrome.
    Di Carli MF; Charytan D; McMahon GT; Ganz P; Dorbala S; Schelbert HR
    J Nucl Med; 2011 Sep; 52(9):1369-77. PubMed ID: 21849399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive family history of coronary artery disease is associated with reduced myocardial vasoreactivity in healthy men.
    Sundell J; Laine H; Raitakari OT; Luotolahti M; Nuutila P; Knuuti J
    Int J Cardiol; 2006 Oct; 112(3):289-94. PubMed ID: 16298443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic determination of TNF and myeloperoxidase production in dialyzed patients with diabetic nephropathy.
    Buraczynska K; Koziol-Montewka M; Majdan M; Tokarz A; Ksiazek A
    Ren Fail; 2004 Nov; 26(6):633-9. PubMed ID: 15600254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of myeloperoxidase -463 G/A gene polymorphism and plasma levels on coronary artery disease.
    Ergen A; İsbir S; Timirci Ö; Tekeli A; İsbir T
    Mol Biol Rep; 2011 Feb; 38(2):887-91. PubMed ID: 20568015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.